Sun Pharmaceutical Industries has launched a novel ophthalmology treatment, CEQUA, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology.
Global clinical trials have shown that CEQUA provides faster results and is comfortable to most of the patients right from the start of treatment. CEQUA is backed by years of clinical experience in the U.S. and other geographies. It is a welcome addition to our treatment toolkit.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
